| Gene/Protein Targets | Estragen receptor (ERT2) under the vascular endothelial cadherin (Cdh5(PAC)) promoter. |
| Relevance: | Cdh5(PAC)-CreERT2 enable efficient inducible conditional recombinase expression in embryonic and adult endothelial cells (tissue-specific loxP knockout/knockin/transgene). The mouse is an ideal tool in the study of gene function in angiogenesis, atherosclerosis and neovascularisation. |
| Model Type: | Deleter |
| Genetic Background: | C57BL/6 or FVB/N |
| Zygosity: | Heterozygous |
| Phenotype Keywords: | |
| Disease Keywords: | Angiogenesis |
| Production Details: | A Cdh5(PAC)-CreERT2 transgene vector, containing a genomic Cdh5(PAC) promoter fragment fused to a CreERT2 cDNA, was injected into fertilised embryos (C57BL/6 or FVB/N). Founder lines were back-crossed to establish mice heterozygous for the Cdh5(PAC)-CreERT2 transgene. |
| References: | Wang et al., 2010. Nature. 27:483-6. PMID: 20445537Read more |
| Notes: | The Cdh5(PAC)-CreERT2 mouse exhibits tissue-specific expression of an inducible Cre-ERT2 fusion protein, enabling tamoxifen-induced Cre recombinase activity in vascular endothelial cells. Administration of tamoxifen induces nuclear translocation of the Cre-ERT2 fusion protein, and subsequent Cre recombinase activity, allowing knockout/knockin/transgene studies of loxP-flanked genes in vascular endothelial cells. Non-induced Cdh5(PAC)-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Cdh5(PAC)-CreERT2 mice demonstrate high penetrance in vascular endothelial cells (95%+). |
© Cancer Research Technology 2012